Vector-based COVID-19 vaccine-associated thrombotic events usually occur within 2 weeks and are often fatal


  • Thrombosis and thrombocytopenia syndrome usually manifests within 2 weeks of exposure to adenovirus vector-based SARS-CoV-2 vaccines and is associated with high mortality rates.

Why this matters

    There is increasing evidence of a relationship between thrombosis and thrombocytopenia syndrome and adenovirus vector-based vaccines against SARS-CoV-2. This is the first systematic analysis of published literature on thrombotic complications following vector-based SARS-CoV-2 vaccines; the findings should not deter rapid vaccination of the population, due to the overwhelmingly favorable risk-benefit ratio for vaccination. Characterization of this syndrome would facilitate rapid diagnosis and intervention that could improve the prognosis of these individuals following vaccination.